Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions

Multiple Myeloma

Interventions

DRUG

Uproleselan

Provided by study

DRUG

Placebo

Provided by study

DRUG

Melphalan

-Standard of care

Trial Locations (1)

Washington University School of Medicine, St Louis

All Listed Sponsors

collaborator

GlycoMimetics Incorporated

INDUSTRY

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

lead

Washington University School of Medicine

OTHER